摘要:
The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFa inhibitor, such as a human TNFa antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFa inhibitor for treatment of psoriatic arthritis in a subject.
摘要:
An injection device comprises a syringe (1) extendible against a spring bias (9) from a retracted position in a housing (2) to a projecting injecting position. A spring biased plunger has collapsible elbows (10) which, when the plunger is released, initially engage the end of the syringe to drive it to the projecting position, whereupon arresting of the syringe movement causes the elbows to collapse inside the syringe to allow the plunger to engage and drive the bung (3).
摘要:
Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.
摘要:
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNF α) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K d = 10. 8 M or less), a slow off rate for hTNFα dissociation (e.g., K off = 10 -3 sec -1 or less) and neutralize hTNFα activity in vitro and in vivo . An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要:
Exemplary embodiments provide a syringe plunger formed of a polymeric material. The syringe plunger includes a pressurizer disposed at a proximal end, and a distal end bifurcated into a first plunger arm having a first conical surface and a second conical surface, and a second plunger arm having a first conical surface and a second conical surface. The distal end includes a first contact surface defined by the first conical surface of the first plunger arm and the first conical surface of the second plunger arm, the first contact surface configured to initially contact a firing engagement mechanism, the first contact surface disposed at a first angle of between about 40° and about 80° relative to a longitudinal axis of the syringe plunger. The distal end also includes a second contact surface defined by the second conical surface of the first plunger arm and the second conical surface of the second plunger arm, the second contact surface configured to contact the firing engagement mechanism subsequent to contact by the first contact surface.
摘要:
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
摘要:
The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.
摘要:
Multiple-variable dose methods for treating TNFalpha-related disorders, including Crohn's disease and psoriasis, comprising administering TNFalpha inhibitors, including TNFalpha antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
摘要:
The invention provides methods, uses and compositions for the treatment of psoriasis or Crohn's disease. The invention describes methods and uses for treating psoriasis or Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. The invention includes methods of improving patient reported outcomes using a human human TNFα antibody, or antigen-binding portion thereof, for the treatment of Crohn's or psoriasis. The invention also provides methods of improving fatigue or depression in patients having Crohns'.